SMAIO

SMAIO Capital Expenditures

The Capital Expenditures (CapEx) of SMAIO (ALSMA.PA) as of Oct 16, 2026 is -1.59 M EUR. In the previous year, Capital Expenditures (CapEx) was -1.55 M EUR — a change of 2.03% (lower).

Capital Expenditures

-1.59 MEUR

YoY

2.03%

Last updated:

Capital Expenditures (CapEx) of SMAIO is 2025 -1.59 M EUR. Capital Expenditures (CapEx) of SMAIO was 2024 -1.55 M EUR. It decreases by 2.03% lower compared to the previous year.

The SMAIO Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2019
-1.65 M EUR
Jan 1, 2020
-1.65 M EUR
Jan 1, 2021
-1.27 M EUR
Jan 1, 2022
-830,260.00 EUR
Jan 1, 2023
-1.15 M EUR
Jan 1, 2024
-1.55 M EUR
Jan 1, 2025
-1.59 M EUR
The SMAIO Capital Expenditures history
YEARCapital ExpendituresYoY
-1.59 MEUR+2.03%
-1.55 MEUR+34.56%
-1.15 MEUR+39.09%
-830,260.00EUR-34.83%
-1.27 MEUR-22.81%
-1.65 MEUR0.00%
-1.65 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SMAIO Stock analysis

What does SMAIO do? SMAIO SA, listed on Euronext Paris under ticker ALSMA.PA with ISIN FR0014005I80, is a health care company headquartered in Saint-Priest, France. Founded in 2022, the company specializes in medical devices for spinal pathologies. SMAIO SA employs 38 full-time staff and completed its initial public offering on April 6, 2022. The company provides surgical solutions for spine physicians, including i-plan for surgical planning, i-perform for surgical procedures, i-check for outcome data, and i-learn for education. SMAIO SA utilizes clinical data and imaging to transform vertebral fusion procedures for spine surgery specialists. The firm offers a comprehensive solution combining software, implantable devices, and associated services to treat spinal conditions requiring surgery. Key products include the Kheiron Spinal Fixation System, designed for immobilization and stabilization of spinal segments during fusion procedures in the thoracic, lumbar, and sacral spine. Additionally, SMAIO SA develops Keops and Balance Analyzer 3D software for surgical planning and patient database management. The company operates within the health care sector, focusing on innovative approaches to spinal surgery. Its website is https://smaio.com/. SMAIO is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SMAIO stock

Capital Expenditures (CapEx) of SMAIO is -1.59 M EUR in 2025.

Capital Expenditures (CapEx) of SMAIO changed from -1.55 M EUR to -1.59 M EUR, representing a 2.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) SMAIO since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s SMAIO historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SMAIO

All Key Metrics — SMAIO